Researcher Annette R. Khaled at the University of Central Florida College of Medicine led a study identifying Chaperonin-containing TCP-1 (CCT/TRiC) as a promising therapeutic and diagnostic target for neuroblastoma. This protein complex plays a key role in cancer cell survival and invasiveness, with high expression levels linked to advanced tumor stages. Targeting CCT2, a key subunit, with a novel inhibitor induced cell death in neuroblastoma cells, highlighting its potential for new treatment and detection strategies in pediatric cancer.
We are proud to partner with the University of Central Florida and some truly amazing and talented individuals to make these research trials possible. We invite you to explore this page to learn about all the incredible, groundbreaking research funded by the Live Like Bella® Pediatric Cancer Research Initiative that will help make pediatric cancer a treatable and curable disease.
Cristina Fernandez-Valle, Ph.D.
Synergistic PI3K combinatorial targeting for NF2 Schwannomas.
Cristina Fernandez-Valle, Ph.D.
Development of an Early Diagnostic Test for Malignant Tumors in Children with NF1.
Li-Mei Chen M.D., Ph.D
Exosome-mediated activation of matriptase targeting B cell lymphoma.
Elias Sayour M.D, Ph.D
Multi-center phase I study evaluating lipid-nanoparticle vaccines against pediatric high-grade glioma.
Coy Heldermon Md, Ph.D
Novel immunologic therapy of soft tissue sarcoma.
Annette Khaled
Evaluating Chaperonin-Containing TCP1 for the Screening of Pediatric Cancer.
Alicja Copik
Elucidation and targeting of epigenetic changes resulting in glucocorticoid resistance in pediatric acute lymphoblastic leukemia.
Griffith Parks, PhD
Oncolytic virus in combination with NK cells for treatment of pediatric cancers.
Annette Khaled
Targeting Chaperonin-containing TCP-1 for the Treatment of Neuroblastoma.
Griffith Parks, PhD
Incucyte® Real-Time Pediatric Cancer Cell Analysis Equipment.
